FDA pregnancy medication categories : Pre 2015.

Mohamad Ali Salloum, PharmD • March 28, 2022

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button

Being pregnant brings to women so many questions. The questions can range from stuff related to how their bodies are affected, what should they eat, how much exercise should be done...etc.


All the questions are important to answer and make it clearer for the pregnant woman to prevent unnecessary bad things from happening. However, one of the most important questions to be asked is “What are the medications that can be administered during pregnancy and what are the medications to be avoided?”


In 1979, the FDA published a classification for the medications to organize them in a clearer way. The classification is called “FDA pregnancy categories” and there are 5 of them: A, B, C, D, and X.


Fast forward to 2015, and after receiving many comments that this categorization leaves the patients and the health care providers confused and may misinterpret the meaning of the letters, the FDA replaced it with new narrative information which will remove the confusion away. Hopefully :D


The new narrative description of medication safety is called the Pregnancy and Lactation Labeling Rule (PLLR).


So, the FDA requested that prescription drugs and biologic products submitted after June 30, 2015, will use the new format immediately. (1)

 

To understand more about why this update happened, let us first explore the previous categorization used. In this article we will talk about the FDA pregnancy risk categories used prior to 2015.


You can go to this article for more details about the 2015 update.

 

Category A (2)


Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).


Example drugs or substances: 


LevothyroxineFolic Acid, Thiamine, Pyridoxine, Doxylamine.


Category B (2)


Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.


Example drugs:


MetforminHydrochlorothiazideCyclobenzaprineAmoxicillin.


Category C (2)


Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.


Example drugs: 


GabapentinAmlodipineTrazodone.


Category D (2)


There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.


Example drugs: 


Losartan, Carbamazepine, Phenytoin.


Category X (2)


Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.


Example drugs: 


AtorvastatinSimvastatinMethotrexateFinasteride, Triazolam, Isotretinoin.



   

As a summary:

Category Safe to Use? Examples
A Yes Paracetamol, Levothyroxine, Folic Acid
B Yes Amoxicillin, Cephalosporins, Metformin
C Do Risk/Benefit assessment Gabapentin, Trazodone, Amlodipine
D Do Risk/Benefit assessment Carbamazepine, Phenytoin, Losartan
X No Atorvastatin, Simvastatin, Ribavirin, Methotrexate

Since you are now familiar with the categories, I think you have an idea why the FDA updated the requirements and why it is causing some confusion about their meaning.


Let’s go and explore the 2015 update and how the FDA is now requesting the pharmaceuticals to write down a narrative assessment in the drug labelling information. Click Here.



List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD March 24, 2026
    This guide breaks down why your body reacts the way it does, how misinterpretation fuels anxiety, and the CBT tools designed to help you understand (and stop fearing) your own physical sensations.
    By Mohamad-Ali Salloum, PharmD March 22, 2026
    This article explains why avoidance is so powerful, how it silently shapes your emotions and behaviors, and evidence‑based strategies that help you break the cycle.
    By Mohamad-Ali Salloum, PharmD March 20, 2026
    Are you having Negative Automatic Thoughts (NATs)? We got you 💆‍♂️
    By Mohamad-Ali Salloum, PharmD March 18, 2026
    Learn how to break the vicious cycle by addressing your behaviors!
    By Mohamad-Ali Salloum, PharmD March 16, 2026
    Low Mood is NOT random!
    By Mohamad-Ali Salloum, PharmD March 15, 2026
    Learn how CBT rewires thoughts, emotions, and behaviors—and test your knowledge with a quick quiz.
    By Mohamad-Ali Salloum, PharmD March 8, 2026
    A clear, engaging walkthrough of fentanyl’s pharmacokinetics and pharmacodynamics—from administration to metabolism and excretion—designed for pharmacy and medical students, with visuals, summaries, and an interactive quiz.
    By Mohamad-Ali Salloum, PharmD March 8, 2026
    Understand Aspirin easily with this blog post.
    By Mohamad-Ali Salloum, PharmD March 7, 2026
    Learn about Buprenorphine, the strong gripper, but weak pusher 😅
    By Mohamad-Ali Salloum, PharmD March 7, 2026
    References : American Chemical Society. Tramadol – Molecule of the Week Archive. December 16, 2014. [acs.org] DEA Diversion Control Division. Tramadol Drug & Chemical Evaluation Section Report. April 2025. [deadiversi....usdoj.gov] Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879‑923. [go.drugbank.com] Food and Drug Administration (FDA). ULTRAM® (tramadol hydrochloride) tablets label. 2004. [accessdata.fda.gov] Nickson C. Tramadol – CCC Pharmacology. Life in the Fast Lane ; 2024. [litfl.com] DrugBank Online. Tramadol: Uses, Interactions, Mechanism of Action. DB00193. [go.drugbank.com] Food and Drug Administration (FDA). Tramadol Hydrochloride Tablets (DailyMed). 2023. [dailymed.nlm.nih.gov] Dean L. Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries . 2015. [ncbi.nlm.nih.gov] Food and Drug Administration (FDA). Tramadol ER Capsules Label Information. 2010. [accessdata.fda.gov] EBM Consult. Mechanism for Tramadol‑Induced Serotonin Syndrome in Patients Taking SSRIs. 2017. Medsafe Pharmacovigilance. Serious Reactions with Tramadol: Seizures and Serotonin Syndrome. 2007. Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018;131(11):1382.e1–6. Medscape Reference. Ultram, ConZip (tramadol) dosing, indications, interactions. 2026.
    More Posts